Anti-TNF-alpha Antibody Engineering for Reduced Immunogenicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current TNFα antibodies used to treat autoimmune and inflammatory conditions exhibit significant immunogenicity, leading to lower drug levels, treatment discontinuation, and reduced efficacy due to the formation of large immune complexes and internalization by antigen-presenting cells.
Innovation Solution
Development of novel anti-TNFα antibodies engineered to prevent the formation of large immune complexes and enhance dissociation from TNFα at acidic pH, thereby reducing immunogenicity and maintaining consistent serum levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional TNFα antibodies are used to treat autoimmune and inflammatory conditions, then therapeutic efficacy is achieved, but significant immunogenicity occurs leading to lower drug levels and treatment discontinuation
Solution Approach 1:
The patent divides the antibody into separate heavy and light chains that can be independently engineered and expressed, allowing optimization of each component to reduce immunogenicity while maintaining therapeutic function. The heavy chain and light chain are designed with specific sequences that minimize human antibody response.
Solution Approach 2:
The patent modifies key parameters of the antibody molecule including amino acid sequences of heavy and light chains, binding affinity to TNFα, and pharmacokinetic properties. These parameter changes result in an antibody that maintains therapeutic efficacy while reducing immunogenicity through optimized molecular characteristics.
2Reliability
If TNFα antibodies bind to TNFα with high affinity, then therapeutic effect is enhanced, but large immune complexes form and are internalized by antigen-presenting cells increasing immunogenicity
Solution Approach 1:
The patent designs the antibody-TNFα interaction with dynamic characteristics where the binding affinity is optimized to maintain therapeutic effect while preventing stable formation of large immune complexes. The antibody can dissociate from TNFα in a controlled manner to prevent uptake by antigen-presenting cells.
Solution Approach 2:
The patent applies different binding characteristics to different regions of the antibody-TNFα complex. The antigen-binding fragments are designed with specific affinity, while the Fc region properties are optimized to prevent immune complex formation and internalization, creating localized functional differences within the overall complex.
3Reliability
If antibody dosage is increased to maintain effective drug levels, then therapeutic efficacy is improved, but immunogenicity increases leading to more rapid clearance
Solution Approach 1:
The patent creates a novel antibody sequence that copies the successful therapeutic characteristics of conventional TNFα antibodies while avoiding their immunogenicity problems. The heavy and light chain sequences are designed to mimic the functional properties of approved antibodies but with modified regions that reduce human antibody response.
Solution Approach 2:
The patent employs a monovalent antibody format that may have shorter half-life but reduces immunogenicity and clearance. This approach treats the antibody as a disposable therapeutic that achieves effective drug levels through optimized pharmacokinetics rather than long-term persistence, reducing the accumulation of immunogenic complexes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered antibodies demonstrate reduced immunogenicity, longer half-life, and improved therapeutic efficacy by inhibiting TNFα stimulation of monocytes and maintaining effective TNFα binding across different pH levels.
Implementation Method 1
engineered to prevent the formation of large immune complexes and enhance dissociation from TNFα at acidic pH
Implementation Method 2
inhibiting TNFα stimulation of monocytes
Data Source
AI summary
This invention relates to anti-TNFα antibodies and methods of using them in treating diseases and conditions related to TNFα activity. e.g., autoimmune or inflammatory conditions.